Following Type C FDA Meeting, Calcimedica Has Aligned On Phase 2b Trial Endpoints And Patient Population Enrichment Strategy For Its Planned Registration Program Evaluating Auxora In Acute Pancreatitis
CalciMedica Inc CALC
$1.00
▲ +19.05%
(+$0.16)
⬆️ Above Yest. High
🎈 Low Float
🗓️ Earnings Next Week
Open
$0.86
Prev Close
$0.84
Day Range
$0.85 – $1.00
52W Range
$0.46 – $7.20
Market Cap
$30.74M
Beta
0.90
EPS (TTM)
$-1.29
📋 Company Profile
| Industry | Pharmaceuticals |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2020-09-25 |
| Shares Out. | 30,740,000 |
| Website | calcimedica.com/ ↗ |
| Phone | 18589525500 |
| Employees | 16 |
| Net Income | $4.9M |
| Free Cash Flow | -$21.2M |
| Total Assets | $8.6M |
| Total Liabilities | $9.7M |
| Equity | -$1.1M |
About CalciMedica Inc
CalciMedica Inc is a clinical-stage biopharmaceutical company focused on developing therapeutics that treat serious illnesses driven by inflammatory and immunologic processes and direct cellular damage. Its product candidates act upon calcium release-activated calcium (CRAC) channels and would constitute a new class of drugs. Its product candidate is Auxora, a potent and selective intravenous formulated small molecule CRAC channel inhibitor containing the active compound zegocractin (formerly referred to as CM4620) that, in animal models, reduced acute epithelial and/or endothelial cell injury and inflammation in organs, such as the pancreas, lungs and kidneys. The company operates as one operating segment focused on developing and commercializing therapeutics in the U.S.
CalciMedica Inc is a publicly traded company under the ticker symbol CALC on the NASDAQ NMS - GLOBAL MARKET, operating in the Pharmaceuticals industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
10 analysts (2026-07-01)